



Reproduction  
in Domestic Animals

**CANINE PROSTATE SPECIFIC ESTERASE (CPSE) AS AN  
USEFUL BIOMARKER IN PREVENTIVE SCREENING PROGRAM  
OF CANINE PROSTATE: CPSE THRESHOLD VALUE  
ASSESSMENT AND ITS CORRELATION WITH  
ULTRASONOGRAPHIC PROSTATIC ABNORMALITIES IN  
ASYMPTOMATIC DOGS**

Journal:	<i>Reproduction in Domestic Animals</i>
Manuscript ID	RDA-OA-Sep-2017-0367.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Alonge, Salvatore; Società Veterinaria "Il Melograno" srl; Università degli Studi di Bari Aldo Moro, Dep. D.E.T.O., Section of Veterinary Clinics and Animal Productions Melandri, Monica; Società Veterinaria "Il Melograno" srl Leoci, Raffaella; Università degli Studi di Bari Aldo Moro, Dep. D.E.T.O., Section of Veterinary Clinics and Animal Productions Lacalandra, Giovanni; Università degli Studi di Bari Aldo Moro, Dep. D.E.T.O., Section of Veterinary Clinics and Animal Productions Aiudi, Giulio ; Università degli Studi di Bari Aldo Moro, Dep. D.E.T.O., Section of Veterinary Clinics and Animal Productions
Subject Area:	Andrology < General reproduction, Endocrinology < General reproduction, dogs/cats < Species:

SCHOLARONE™  
Manuscripts

CANINE PROSTATE SPECIFIC ESTERASE (CPSE) AS AN USEFUL BIOMARKER IN  
PREVENTIVE SCREENING PROGRAM OF CANINE PROSTATE: CPSE THRESHOLD  
VALUE ASSESSMENT AND ITS CORRELATION WITH ULTRASONOGRAPHIC PROSTATIC  
ABNORMALITIES IN ASYMPTOMATIC DOGS.

Salvatore ALONGE, DVM<sup>1,2</sup>, PhD, Monica MELANDRI, DVM<sup>1</sup>, Raffaella LEOCI, DVM, PhD<sup>2</sup>,

Giovanni Michele LACALANDRA DVM<sup>2</sup>, Giulio AIUDI, DVM, PhD<sup>2</sup>

<sup>1</sup>Società Veterinaria “Il Melograno” srl, Sesto Calende (VA), Italy;

<sup>2</sup>Dep. D.E.T.O., Section of Veterinary Clinics and Animal Productions, University of Bari “Aldo Moro”, Italy.

e-mail: drsalvatorealonge@gmail.com, monica.melandri@email.it, leocivet@yahoo.it;

giovannimichele.lacalandra@uniba.it, giulioaiudi@uniba.it

Corresponding Author:

Salvatore Alonge  
Dep. D.E.T.O.,  
Section of Veterinary Clinics and Animal Productions,  
University of Bari “Aldo Moro”, Italy.  
Phone +39 392.8058524  
e-mail [drsalvatorealonge@gmail.com](mailto:drsalvatorealonge@gmail.com)

## 1 STRUCTURED SUMMARY

2 Due to the increased attention that pet-owners devote to their animals and to the improved  
3 veterinary care, investigations regarding methods to early detect prostatic disorders that might affect  
4 canine life quality have been performed. Canine Prostatic Serum Esterase concentration (CPSE)  
5 was reported to be higher in dogs suffering from prostatic diseases. This study aimed to estimate the  
6 canine-prostate specific arginine esterase (CPSE) threshold as biomarker to early identify prostatic  
7 diseases in asymptomatic dogs. The ultrasonographic exam of the prostate was performed in 19  
8 dogs (6-40 kg; 1-5 years) with no symptoms of prostatic diseases. Dogs were grouped according to  
9 the presence (group A) or absence (group B) of prostatic disorders at ultrasound (altered  
10 appearance, presence of cysts or irregular borders). For each dog, a venous blood sample was  
11 collected to measure serum CPSE and the ratio between calculated and normal expected prostatic  
12 volume was assessed for each dog. The CPSE data were statistically analyzed (t-Test,  $p < 0.05$ ) and  
13 the CPSE threshold in blood serum between groups was calculated by ROC. In 11 dogs,  
14 ultrasonography showed signs of prostatic abnormalities (group A, 2-5 years) while no signs were  
15 detected in 8 dogs (group B, 1-3 years). The calculated/estimated volume ratio resulted greater than  
16 1.5 in group A dogs. The CPSE was statistically different between groups ( $p < 0.0001$ ): higher in  
17 group A (mean=184.9, SD=126 ng/ml) than in group B ( $38.9 \pm 22.1$  ng/ml). The cut-off CPSE  
18 threshold was 52.3 ng/ml (ROC, AUC=0.974, SE 95.6%, SP 89.2%). This study suggests that CPSE  
19 serum concentration higher than 50 ng/ml in asymptomatic dogs is associated with ultrasonographic  
20 alterations and increased prostatic size (volume by 1.5 times greater than the normal size). Since the  
21 onset of prostatic disorders often remains asymptomatic, the rapid assessment of CPSE could be  
22 suitable for selecting preventively those animals that would require further accurate evaluation.

23 **Running head:** CPSE a biomarker for the canine prostatic health screening.

24 **Keywords:** CPSE, dog, ultrasonography, prostatic disease.

## 25 INTRODUCTION

26 Due to the increased attention that pet-owners devote to their animals and to the improved  
27 veterinary care, investigations regarding methods to early detect prostatic disorders that might affect  
28 the life quality of the dogs have been performed (Mukaratirwa and Chitura, 2007; Levy et al., 2014;  
29 Mantziaras et al., 2017). The most relevant clinical diseases of the gland are benign prostatic  
30 hyperplasia, prostatic cyst, prostatitis and prostatic neoplasia (Johnston et al., 2001). Since the  
31 canine prostatic diseases are symptomless in their onset and difficult to be diagnosed in their early  
32 stage, most of the times they are recognized at advanced stage (Johnston et al., 2000; Mantziaras et  
33 al., 2017). In men, due to the improved diagnostic tools, such as the serum prostate specific antigen  
34 (PSA) test, the early recognition of subclinical cases (with no clinical symptoms) increases the  
35 incidence of diagnosed prostatic diseases (Mukaratirwa and Chitura, 2007). For this reason, several  
36 authors focused their attention on the identification of canine serum marker similar to those  
37 routinely used in human medicine (Chapdelaine et al., 1984; Levy and Mimouni, 2009; Holst et al.,  
38 2017). Since '90, it was suggested that the Canine Prostatic Serum Esterase concentration (CPSE),  
39 that represents the major secretory product of the canine prostatic gland could be a useful diagnostic  
40 biomarker to identify dogs suffering from prostatic diseases (Chapdelaine et al., 1984; Bell et al.,  
41 1985). More recently several authors reported that higher CPSE was observed in dogs suffering  
42 from prostatic disorders such as benign prostatic hyperplasia (BPH), bacterial prostatitis or prostatic  
43 carcinoma (Teintflat et al., 2000; Levy and Mimouni, 2009; Wolf et al., 2012) and among these  
44 abnormalities, benign prostatic hyperplasia (BPH) represents the most common physio-pathological  
45 alteration of the gland (Levy et al., 2014). The diagnosis is usually based on clinical signs in  
46 combination with an enlarged gland. In clinical veterinary practice, the most commonly used  
47 methods to diagnose canine prostatic gland diseases are digital rectal examination and abdominal  
48 ultrasound (Newell et al., 1998; Mukaratirwa and Chitura, 2007; Mantziaras et al., 2017). Recently  
49 some authors suggested that the monitoring of local blood flow by Doppler or Contrast-Enhanced  
50 UltraSonography is helpful in differentiating prostatic physio-pathological conditions (Bigliardi and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 Ferrari 2011; Russo et al., 2012; Troisi et al., 2015; Alonge et al., 2017). Cytological evaluation by  
52 fine-needle aspiration or biopsy of the prostate is usually performed to confirm the benign nature of  
53 the prostate volume enlargement (Kraft et al., 2005; Paclikova et al., 2006; Davidson and Baker,  
54 2009; Levy et al., 2014). Nevertheless, some dogs might have an enlarged prostate without  
55 symptoms (Russo et al., 2012). For this reason, a prostate health-screening program could obtain a  
56 more reliable estimation of the prevalence of canine prostatic disorders and the CPSE might be a  
57 potentially suitable biomarker for this purpose in dogs, as in men. Thus, the aim of this study was to  
58 estimate the CPSE threshold to be used in clinical practice to early identify prostatic diseases in  
59 clinically asymptomatic dogs with just ultrasonographic signs of prostatic disorders.  
60

## 61 MATERIALS AND METHODS

### 62 Animals

63 Nineteen dogs of different breeds (BW: 6-40 kg, age: 1-5 years) with no symptoms of prostatic  
64 diseases were included in this study. Each dog underwent clinical examination including a thorough  
65 history, and a rectal exploration of the prostate. All were healthy.  
66

### 67 Procedure

68 In each dog, a venous blood sample was collected from the cephalic vein to measure serum CPSE  
69 (Speed CPSE, Virbac, Italy). Samples were stored at -20 °C until CPSE was analyzed using a  
70 commercial assay (Speed Reader, Virbac, Italy).

71 For the ultrasonography evaluation, dogs were positioned in lateral recumbency, transmission gel  
72 was applied, and two-dimensional, gray-scale, real-time ultrasound images were produced using a  
73 5-7.5 MHz microconvex probe (MyLab™ClassC, Esaote Spa, Genua, Italy). Ultrasonographic  
74 prostate appearance, border and volume were evaluated as reported in the literature (Davidson and  
75 Baker, 2009). The ultrasonography exam allowed an accurate evaluation of the prostate for changes  
76 in its normal position, parenchyma, symmetry and shape.

1  
2 77 The normal intact canine prostate gland is mainly located in the pelvic region and only the cranial  
3  
4 78 part of the gland is located in the abdominal cavity. The echogenicity, similar to that in the spleen, is  
5  
6 79 fairly uniform with a smooth, stippled texture. Its shape is symmetrically bilobed in the transverse  
7  
8 80 plane and oval in the longitudinal plane (Gobello and Corrada, 2002; Davidson and Baker, 2009).

9  
10  
11 81 Dogs were grouped according to the presence (group A) or absence (group B) of ultrasonographic  
12  
13 82 signs of prostatic disorders (i.e. altered appearance, border, cysts).

14  
15 83 The ratio between the calculated prostatic volume (according to the formula published by Ruel *et*  
16  
17 84 *al.*, 1998: volume = length x width x height x 0.523) (Ruel *et al.*, 1998) and the estimated normal  
18  
19 85 volume (according to the formula suggested by Sannamwong *et al.*, 2012: expected normal volume  
20  
21 86 = 0.33 x BW (Kg) + 3.28) (Sannamwong *et al.*, 2012) was assessed for each dog.  
22  
23

24 87

#### 25 26 88 Statistical analysis

27  
28 89 The normal distribution of CPSE data in the two groups was assessed and CPSE values were  
29  
30 90 statistically compared (t-Test,  $p < 0.05$ ). The CPSE threshold in blood serum between groups was  
31  
32 91 calculated by a Receiver Operating Characteristic analysis: web-based calculator for ROC curves  
33  
34 92 (Eng, 2017).  
35  
36

37 93

## 38 39 94 **RESULTS**

40  
41 95 As reported in table 1, 11 out of the 19 dogs examined, showed ultrasonographically altered prostate  
42  
43 96 (group A, 2-5 years). Five dogs out from the eight dogs that showed cysts, presented also one or  
44  
45 97 more other US abnormalities [altered parenchyma echogenicity (n.=3), asymmetrical lobes (n.=1),  
46  
47 98 gland border alteration (n.=3)]. Three dogs presented altered echotexture/echogenicity and/or  
48  
49 99 irregular gland borders. Finally, in the remaining eight dogs (group B, 1-3 years) prostate was  
50  
51 100 considered normal. The calculated/estimated volume ratio resulted greater than 1.5 in all group A  
52  
53 101 dogs and lower than this threshold in all the dogs of group B. The CPSE was statistically different  
54  
55  
56  
57  
58  
59  
60

102 between groups ( $p < 0.0001$ ), being higher in group A (mean  $\pm$  SD,  $184.9 \pm 126$  ng/ml) than in group  
103 B (mean  $\pm$  SD,  $38.9 \pm 22.1$  ng/ml).

104 The cut-off for the CPSE threshold in blood serum between group A and B from the web-based  
105 calculator for ROC curves (Eng, 2017) resulted 52.3 ng/ml (AUC=0.974, SE 95.6%, SP 89.2%)  
106 (Fig. 1).

## 108 DISCUSSION

109 This study confirms that CPSE represents a useful tool to early detect prostatic disorders in dogs.  
110 Some authors have previously suggested that prostate size could be affected by age, breed, and  
111 body weight, but also by the emergence of pathologic processes, making the establishment of  
112 normal dimensions difficult because of the wide variety of canine sizes, breeds and conditions  
113 (O'Shea, 1962; Cartee and Rowels, 1983; Atalan et al., 1999; Smith, 2008; Freitas et al., 2015).

114 Several studies were performed in order to correctly establish the actual prostatic volume, through  
115 the two dimensional ultrasonographic prostatic measures. (Ruel et al., 1998; Atalan et al., 1999;  
116 Kamolpatana et al., 2000; Gobello and Corrada 2002). Moreover, it was stated that the  
117 ultrasonographic exam is a highly dependent diagnostic imaging modality whose measurements  
118 accuracy might depend by the operator's ability and experience (Leroy et al., 2013). Thus, recently  
119 the Computed Tomography exam of the prostate was proposed (Dimitrov et al., 2010; Lee et al.,  
120 2011; Pasikowsha et al., 2015). The Computed Tomography examination would allow a more  
121 precise and repeatable measurements inter-observers, but it is less accessible, more expensive and  
122 time consuming, and requires general anesthesia (Pasikowsha et al., 2015). On the other hand, the  
123 ultrasonographic exam of the canine prostate is non-invasive and fast and so it remains the  
124 diagnostic imaging tool of choice for the evaluation of this organ (Mantziaras et al., 2017). Anyway,  
125 for all these reasons, since a clear threshold measure to identify the normal volume of the canine  
126 prostate dogs does not exist, in the present study dogs were grouped in accordance to

1  
2 127 presence/absence of other ultrasonographical abnormal findings (i.e. altered appearance, border,  
3  
4 128 cysts).  
5  
6 129 Almost the 60% of the asymptomatic dogs presented at the ultrasonography an altered prostate  
7  
8 130 (Group A) while the gland resulted echographically normal in the remaining 40% of the animals  
9  
10 131 (Group B). This result confirms that prostatic disorders often remain asymptomatic, therefore may  
11  
12 132 be under-estimated (Levy et al., 2014; Polisca et al., 2016; Mantziaras et al., 2017). Due to the lack  
13  
14 133 of pathognomical clinical signs, at least at their onset, in the general dog population prostatic  
15  
16 134 disorders often go unnoticed, while these abnormalities are diagnosed more frequently in dogs  
17  
18 135 presented for poor fertility evaluation (Polisca et al., 2016). In this last case, an ultrasonographic  
19  
20 136 exam of the prostate is strongly recommended when a presumptive diagnosis of BPH is based on  
21  
22 137 detection of blood in prostatic fluid of the ejaculate or in case of a presumptive diagnosis of chronic  
23  
24 138 prostatitis based on signs of infertility or decreased libido (Johnston et al., 2000; Lopate, 2012).  
25  
26 139 Present results show that prostate affected by ultrasonographically detectable abnormalities show a  
27  
28 140 volume at least 1.5 times greater than the normal expected volume. Many dogs do not exhibit  
29  
30 141 clinical signs even in case of hyperplastic growth of the gland (Palmieri et al., 2014), most likely  
31  
32 142 because the outward expansion of the canine prostate (McConnell, 1991) compared to the inward  
33  
34 143 nodular growth that compress the urethra in men (McNeal, 1978). Recently, it was suggested that  
35  
36 144 dogs with a prostatic calculated volume higher than 2.5 times greater than the normal expected  
37  
38 145 volume present clinical signs and a CPSE concentration higher than 90 ng/ml (Holst et al., 2017).  
39  
40 146 In the present study the concentration of CPSE was significantly associated with the presence of  
41  
42 147 prostatic abnormal findings that could be identified by the ultrasound exam. Although, a  
43  
44 148 histological confirmation of prostatic disease would have been desirable to definitively confirm the  
45  
46 149 diagnosis, it is nearly impossible also in everyday routine practice when no one owner would agree  
47  
48 150 to perform a more invasive procedure in an asymptomatic and apparently healthy dog, such as the  
49  
50 151 prostate biopsy. On the other hand, the CPSE is a known marker for prostatic secretion, that can be  
51  
52 152 easily assessed by a simple blood serum sample. It constitutes more than 90% of seminal proteins in  
53  
54  
55  
56  
57  
58  
59  
60



1  
2 153 dogs, but its exact role in the different prostatic disorders is not yet completely understood (Frenette  
3  
4 154 et al., 1987; Gobello et al., 2002). Recently, it was suggested that the CPSE is secreted in the form  
5  
6 155 of prostatesomes (prostate granules) to semen during ejaculation. The activity of CPSE is regulated  
7  
8 156 by the level of available zinc that is of great importance for maintaining the normal functions of the  
9  
10 157 prostate and the spermatozoa. (Mogielnicka-Brzozowska et al., 2015). The production of CPSE is  
11  
12 158 regulated by androgen hormone (testosterone), it can be inhibited by the surgical castration or anti-  
13  
14 159 androgen treatment (Frenette et al., 1983; Isaacs and Sharper; 1985; Juniewicz et al., 1990) or  
15  
16 160 promoted by the exogenous androgen administration following the surgical castration (Frenette et  
17  
18 161 al., 1983; Isaacs and Sharper; 1985). Thus, the canine CPSE and the human PSA, even though their  
19  
20 162 different biological activity (CPSE: trypsin-like; PSA: chymotrypsin-like), are under identical  
21  
22 163 hormonal regulation (Dube et al., 1986; Clement, 1989). Moreover, for this reason the CPSE seems  
23  
24 164 to be a promising diagnostic tool for the detection of prostatic disorders in a “prostate health  
25  
26 165 screening program” similarly to PSA in human medicine (Gobello et al., 2002).  
27  
28  
29  
30 166 Recently, it was suggested that, in dogs over the 40% of the maximum expected longevity for the  
31  
32 167 breed, a preventive ultrasonographic screening program would be advisable (Mantziaras et al.,  
33  
34 168 2017). In that study, the authors reported a strong probability to detect prostatic abnormal findings  
35  
36 169 by ultrasonographic exam irrespective of clinical evidence (Mantziaras et al., 2017).  
37  
38  
39

## 40 170 **CONCLUSIONS**

41  
42  
43 171 Results of the present study indicate that serum concentration higher than 50 ng/ml in asymptomatic  
44  
45 172 dogs is associated with ultrasonographic alterations and increased prostate size (volume by 1.5  
46  
47 173 times greater than the normal size). In clinical practice, since the onset of prostatic disorders, such  
48  
49 174 as BPH, often remains asymptomatic until aggressive therapy is required, the rapid assessment of  
50  
51 175 CPSE could be suitable like a preventive screening tool to select preventively those animals that  
52  
53 176 would require further more accurate, more time-consuming and more expensive evaluations before  
54  
55  
56 177 clinical signs appear.  
57  
58  
59  
60

1  
2 178  
3  
4

5 179 **DECLARATIONS - Ethical Guidelines committee**  
6

7  
8 180 The present study was performed in accordance with the ethical guidelines of the animal welfare  
9  
10 181 committee. Institutional Review Board approval of the study was obtained by the University of Bari  
11  
12 182 “Aldo Moro”, Ethic Committee DETO, Italy (Protocol N° 35/17 DETO; 26/06/2017). Procedures  
13  
14 183 with animals were performed following good veterinary practice for animal welfare according to  
15  
16 184 national laws in force (D.Lgs 116/92). Informed owner consent was obtained.  
17

18  
19  
20 185 **Authors' contributions**  
21

22  
23 186 All authors contributed to design the study, collect, analyze the data and draft the paper. All authors  
24  
25 187 have approved the final version.  
26

27  
28 188 **Competing Interests**  
29

30  
31 189 None of the authors of this article has a financial or personal relationship with other people or  
32  
33 190 organizations that could inappropriately influence or bias the content of the paper.  
34

35  
36 191  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

192 **REFERENCES**

- 193 Alonge, S., Melandri, M., Fanciullo, L., Lacalandra, G., Aiudi, G. (2017) Prostate vascular flow: the  
194 effect of the ejaculation on the power doppler ultrasonographic examination. *Reprod Domest Anim*,  
195 DOI: 10.1111/rda.13078;
- 196 Atalan, G., Holt, P. E., Barr, F. J. (1999). Ultrasonographic estimation of prostate size in normal  
197 dogs and relationship to bodyweight and age. *J Small Anim Pract*, 40, 110–122;
- 198 Bell, F. W., Klausner, J. S., Hayden, D. W., Lund, E. M., Liebenstein, B. B., Feeney, D. A.,  
199 Johnston, S. D., Shivers, J. L., Ewing, C. M., Isaacs, W. B. (1985). Evaluation of serum and seminal  
200 plasma markers in the diagnosis of canine prostatic disorders. *J Vet Intern Med*, 9, 149–153;
- 201 Bigliardi, E., Ferrari, L. (2011). Contrast-enhanced ultrasound of the normal canine prostate gland.  
202 *Vet Radiol Ultrasound*, 52, 107-110;
- 203 Cartee, R. E., Rowels, T. (1983). Transabdominal sonographic evaluation of the canine prostate. *Vet*  
204 *Radiol*, 24, 156–164;
- 205 Chapdelaine, P., Dube, J. Y., Frenette, G., Tremblay, R. R. (1984). Identification of arginine esterase  
206 as the major androgen-dependent protein secreted by dog prostate and preliminary molecular  
207 characterization in seminal plasma. *J Androl*, 5, 206-210;
- 208 Clement, J. A. (1989). The glandular kallikrein family of enzymes: tissue-specific expression and  
209 hormonal regulation. *Endocrinol Rev*, 10, 39-419;
- 210 Davidson, A. P., Baker, T. W. (2009). Reproductive Ultrasound of the dog and tom. *Top Companion*  
211 *Anim Med*, 24, 64-70;
- 212 Dimitrov, R., Yonkova, P., Vladova, D., Kostrov, D. (2010). Computed tomography imaging of the  
213 topographical anatomy of canine prostate. *Trakia J Sci*, 8, 78-82;
- 214 Dube, J. Y., Lazure, C., Tremblay, R. R. (1986). Dog prostate arginine esterase is related to human  
215 prostate-specific antigen. *Clin Invest Med*, 9, 51-54;

- 1  
2 216 Eng, J. (2017). ROC analysis: web-based calculator for ROC curves. Baltimore: Johns Hopkins  
3  
4 217 University. Available from: <http://www.jrocfits.org>;  
5  
6 218 Freitas, L.A., Pinto, J. N., Silva, H. V. R., Machado da Silva, L. D. (2015). Two-dimensional and  
7  
8 219 Doppler sonographic prostatic appearance of sexually intact French Bulldogs. *Theriogenology*, 83,  
9  
10 220 1140–1146;  
11  
12 221 Frenette, G, Dube, J. Y., Lacoste, D., Tremblay, R. R. (1987). Radioimmunoassay in blood plasma  
13  
14 222 of arginine esterase: the major secretory product of dog prostate. *Prostate*, 10, 145:152;  
15  
16 223 Frenette, G, Dube, J. Y., Marcotre, J. R., Tremblay R. R. (1983). Effects of castration and steroid  
17  
18 224 synthesis on the activity of some hydrolytic enzymes in the dog prostate. *Prostate*, 4, 206-210;  
19  
20 225 Gobello, C., Castex, G, Corrada, Y. (2002). Serum and seminal markers in the diagnosis of  
21  
22 226 disorders of the genital tract of the dog: a mini-review. *Theriogenology*, 57, 1285-1291;  
23  
24  
25  
26 227 Gobello, C., Corrada, Y. (2002). Noninfectious prostatic diseases in dogs. *Compend Contin Educ*  
27  
28 228 *Vet*, 2, 99-107;  
29  
30  
31 229 Holst, B. S., Holmroos, E., Frilling, L., Hanas, S., Langborg, L. M., Franko, M. A., Hansson, K.  
32  
33 230 (2017). The association between the serum concentration of canine prostate specific esterase  
34  
35 231 (CPSE) and the size of the canine prostate. *Theriogenology*, 93, 33-39;  
36  
37  
38 232 Isaacs, W., Sharper, J. H. (1985). Immunological localization and quantification of the androgen  
39  
40 233 dependent secretory protease of canine prostate. *Endocrinology*, 117:1512-1520;  
41  
42  
43 234 Johnston, S. D., Kamolpatana, K., Root-Kustritz, M. V., Johnston, G. R. (2000). Prostatic disorders  
44  
45 235 in the dog. *Anim Reprod Sci*, 60-61, 405-415;  
46  
47  
48 236 Johnston, S. D., Root-Kustritz, M. V., Olson, P. N. (2001). Disorders of the canine  
49  
50 237 prostate. In: Johnston, S. D., Root-Kustritz, M. V., Olson, P. N. (Eds.) *Canine and feline*  
51  
52 238 *theriogenology*. Saunders Co, Philadelphia; 2001 pp 337–355;  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2 239 Juniewicz, P. E., Barbolt, T. A., Egy, M. A., Frenette, G., Dube, J. Y., Tremblay, R. R. (1990).  
3  
4 240 Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase. *Prostate*, 17,  
5  
6 241 101-11;  
7  
8  
9 242 Kamolpatana, K., Johnston, G. R., Johnston, S.D. (2000). Determination of canine prostatic volume  
10  
11 243 using transabdominal ultrasonography. *Vet Radiol Ultrasound*, 41, 73-77;  
12  
13  
14 244 Kraft, M., Brown, H.M., LeRoy, B. (2005). Citology of the canine prostate. *Ir Vet J*, 5, 320-324;  
15  
16  
17 245 Lee, K. J., Shimizu, J., Kishimoto, M., Kadohira, M., Iwasaki, T., Miyake, Y. I., Yamada, K. (2011).  
18  
19 246 Computed tomography of the prostate gland in apparently healthy entire dogs. *J Small Anim Pract*,  
20  
21 247 52, 146-151;  
22  
23  
24 248 Leroy, C., Conchou, F., Layssol-Lamour, C., Deviers, A., Sautet, J., Concordet, D., Mogenicato, G.  
25  
26 249 (2013). Normal canine prostate gland: repetibility, reproducibility, observer-dependent variability of  
27  
28 250 ultrasonographic measurements of the prostate in healthy intact beagles. *Anat Histol Embryol*, 42,  
29  
30 251 355-361;  
31  
32  
33 252 Levy, X., Mimouni, P. (2009). Hyperplasie benigne de la prostate: actualites. *Le point veterinaire*,  
34  
35 253 293, 39-43;  
36  
37  
38 254 Levy, X., Nizanski, W., von Heimendahl, A., Mimouni, P. (2014). Diagnosis of common prostatic  
39  
40 255 conditions in dogs: an update. *Reprod Domest Anim*, 49 (Suppl 2), 50-57;  
41  
42  
43 256 Lopate, C. (2012). The problem stud dog. *Vet Clin North Am Small Anim Pract*, 42, 469-488;  
44  
45  
46 257 Mantziaras, G., Alonge, S., Faustini, M., Luvoni, G. C. (2017). Assessment of the age for a  
47  
48 258 preventive ultrasonographic examination of the prostate in the dog. *Theriogenology*, 100, 114 – 119;  
49  
50 259 McConnell, J. D. (1991). The pathophysiology of benign prostatic hyperplasia. *J Androl*, 12, 356–  
51  
52 260 363;  
53  
54  
55 261 McNeal, J. E. (1978). Origin and evolution of benign prostatic enlargement. *Invest Urol*, 15, 340–  
56  
57 262 345;  
58  
59  
60

- 1  
2 263 Mogielnicka-Brzozowska, M., Kowalska, N., Fraser, L., Kordan, W. (2015). Proteomic  
3  
4 264 characterization of zinc-binding proteins of canine seminal plasma. *Reprod Domest Anim*, 50,  
5  
6 265 1017-1021;  
7  
8  
9 266 Mukaratirwa, S., Chitura, T. (2007). Canine subclinical prostatic disease: histological prevalence  
10  
11 267 and validity of digital rectal examination as a screening test. *J S Afr Vet Assoc*, 78, 66-68;  
12  
13  
14 268 Newell, S. M., Neuwirth, L., Ginn, P. E., Roberts, G. D., Prime, L. S., Harrison, J. M. (1998).  
15  
16 269 Doppler ultrasound of the prostate in normal dogs and in dogs with chronic lymphocytic-  
17  
18 270 lymphoplasmic prostatitis. *Vet Radiol Ultrasound*, 39, 332-334;  
19  
20  
21 271 O'Shea, J. D. (1962). Studies on the canine prostate gland. I. Factors influencing its size and  
22  
23 272 weight. *J Comp Pathol*, 72, 321-31;  
24  
25  
26 273 Palmieri, C., Lean, F. Z., Akter, S. H., Romussi, S., Grieco, V. (2014). A retrospective analysis of  
27  
28 274 111 canine prostatic samples: histopathological findings and classification. *Res Vet Sci*, 97,568-573;  
29  
30  
31 275 Paclikova, K., Kohout, P., Vlasin, M. (2006). Diagnostic possibilities in the management of canine  
32  
33 276 prostatic disorders. *Vet Med*, 51, 1-13;  
34  
35  
36 277 Pasikowska, J., Hebel, M., Nizanski, W., Nowak, M. (2015) Computed tomography of the prostate  
37  
38 278 gland in healthy intact dogs and dogs with benign prostatic hyperplasia. *Reprod Domest Anim*, 50,  
39  
40 279 776-783;  
41  
42  
43 280 Polisca, A., Troisi, A., Fontaine, E., Menchetti, L., Fontbonne, A. (2016). A retrospective study of  
44  
45 281 canine prostatic diseases from 2002 to 2009 at the Alfort Veterinary College in France.  
46  
47 282 *Theriogenology*, 85, 835-840;  
48  
49  
50 283 Ruel, Y., Barthez, P. Y., Mailles, A., Begon, D. (1998). Ultrasonographic evaluation of the prostate  
51  
52 284 in healthy intact dogs. *Vet Radiol Ultrasound*, 39, 212-216;  
53  
54  
55 285 Russo, M., Vignoli, M., England, G. C. (2012). B-mode and contrast-enhanced ultrasonographic  
56  
57 286 findings in canine prostatic disorders. *Reprod Domest Anim*, 47(Suppl 6), 238-242;  
58  
59  
60

- 1  
2 287 Sannamwong, N., Saengklub, N., Sriphuttathachot, P., Ponglowhapan, S. (2012). Formula derived  
3  
4 288 prostate volume determination of normal healthy intact dogs in comparison to dogs with clinical  
5  
6 289 BPH. In: England, G., Kutzler, M., Comizzoli, P., Nizanski, W., Rijsselaere, T., Concannon, P., eds.  
7  
8 290 7th international symposium on canine and feline reproduction. Whistler, Canada, p 226;  
9  
10  
11 291 Smith, J. (2008). Canine prostatic disease: a review of anatomy, pathology, diagnosis, and  
12  
13 292 treatment. *Theriogenology*, 70, 375–383;  
14  
15  
16 293 Teintflat, M., Miller, I., Loupal, G., Thalhamme, J. G., Gemeiner, M. (2000). Quantitative  
17  
18 294 determination of canine prostatic-specific protein and its clinical relevance. *Tierarztlinche Praxis*  
19  
20 295 Ausgabe Kleintiere, 28, 127-131;  
21  
22  
23 296 Troisi, A., Orlandi, R., Bargellini, P., Menchetti, L., Borges, P., Zelli, R., Polisca, A. (2015)  
24  
25 297 Contrast-enhanced ultrasonographic characteristics of the diseased canine prostatic gland.  
26  
27 298 *Theriogenology*, 84, 1423-1430;  
28  
29  
30 299 Wolf, K., Kayacelebi, H., Urhausen, C., Piechotta, M., Mischke, R., Kramer, S., Einspanier, A., Oei,  
31  
32 300 C. H., Guenzel-Apel, A. (2012). Testicular steroids, prolactin, relaxin and prostate gland markers in  
33  
34 301 peripheral blood and seminal plasma of normal dogs and dogs with prostatic hyperplasia. *Reprod*  
35  
36 302 *Domest Anim*, 47(Suppl 6), 243-246.  
37  
38  
39  
40 303  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

304 Figure 1. The cut-off for the CPSE threshold in blood serum between group A and group B from the  
305 web-based calculator for ROC curves (Eng, 2017).  
306

For Peer Review



1  
2 307 Table 1. Canine Prostatic Specific Esterase serum concentration and measurements of the prostate  
3  
4 308 in the 19 dogs ultrasonographically examined grouped according Presence (Group A) or absence  
5  
6 309 (Group B) of abnormal ultrasonographic findings (altered appearance, cysts or irregular borders).  
7  
8  
9 310  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

Dog	Age years	Breed	BW Kg	CPSE ng/ml	Abnormal findings	H cm	L cm	W cm	Ruel et al 1998	Sannamwong et al 2012	Volume ratio	Group
1	1	weimaraner	29	11.49	no	1.88	2.14	2.60	5.47	12.85	0.43	B
2	1	dachshund	6	47.26	no	1.86	2.23	2.45	5.31	5.26	1.01	B
3	1.35	pointer	20	45.00	no	3.19	2.33	3.03	11.78	9.88	1.19	B
4	1	mongrel	30.4	78.36	no	2.65	3.87	3.28	17.59	13.31	1.32	B
5	3	weimaraner	31.5	49.10	no	3.08	3.43	3.32	18.34	13.68	1.34	B
6	2	weimaraner	34	38.96	no	3.77	2.81	3.71	20.53	14.50	1.42	B
7	3	weimaraner	30.5	9.65	no	3.08	3.79	3.11	18.99	13.35	1.42	B
8	1.4	pointer	20	31.88	no	3.18	2.53	3.40	14.31	9.88	1.45	B
9	2.5	labrador	34	75.52	yes	2.89	3.85	3.85	22.37	14.50	1.54	A
10	3	husky	25.5	178.39	yes	3.50	2.67	3.75	18.33	11.70	1.57	A
11	2.5	bracco	28	52.30	yes	2.97	3.40	3.80	20.07	12.52	1.60	A
12	2	weimaraner	34	289.51	yes	3.55	3.23	4.14	24.83	14.50	1.71	A
13	5	mongrel	37	120.95	yes	3.42	3.22	4.76	27.42	15.49	1.77	A
14	4	rottweiler	40	200.62	yes	3.00	3.96	4.91	30.51	16.48	1.85	A

15	4	rottweiler	40	236.27	yes	3.56	3.45	4.85	31.15	16.48	1.89	A
16	2.4	chow chow	30	115.54	yes	3.01	4.20	4.00	26.45	13.18	2.01	A
17	5.5	german sh.	36.5	171.93	yes	3.28	4.98	4.61	39.38	15.33	2.57	A
18	3.5	bouledogue	12.8	92.47	yes	2.80	3.70	3.95	21.40	7.50	2.85	A
19	4	amstaff	32.5	500.00	yes	3.44	5.73	5.77	59.48	14.01	4.25	A

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. The cut-off for the CPSE threshold in blood serum between group A and group B from the web-based calculator for ROC curves (Eng, 2017).

101x97mm (128 x 128 DPI)





**DIPARTIMENTO DELL'EMERGENZA  
E DEI TRAPIANTI DI ORGANI (D.E.T.O.)**

DIRETTORE: Prof. Francesco GIORGINO

Segretaria Amministrativa:

Dott.ssa Delfina Maria Misuraca

Tel+Fax 080 5478627

e-mail: [segret.am@deto.uniba.it](mailto:segret.am@deto.uniba.it)

**Sezioni**

Anatomia Patologica  
Anestesia e Rianimazione  
Cardiochirurgia  
Chirurgia d'urgenza  
Chirurgia Generale e Oncologia Clinica  
Chirurgia Generale e Trapianti di Fegato  
Chirurgia Plastica e Ricostruttiva  
Chirurgia Toracica  
Chirurgia Vascolare  
Cliniche Veterinarie e Produzioni Animali  
Ematologia con Trapianto  
Gastroenterologia  
Malattie dell'Apparato Cardiovascolare  
Medicina Interna, Allergologia ed Immunologia Clinica  
Medicina Interna, Endocrinologia, Andrologia e Malattie Metaboliche  
Nefrologia, Dialisi e Trapianti  
Urologia e Andrologia  
Urologia, Andrologia e Trapianti di Rene

**Responsabili**

G.Caruso  
F.Bruno  
L.De Luca Tuppiti  
N.Palasciano  
M.Nacchiero  
V.Memeo  
M.Pascone  
M.Loizzi  
G.Regina  
A.Crovace  
G.Specchia  
A.Di Leo  
S.Favale  
S.Antonaci  
F.Giorgino  
L.Gesualdo  
A.Pagliarulo  
M.Battaglia

To the Editor of Reproduction in Domestic Animals

Bari, October 11<sup>th</sup>, 2017

Dear Editor,

please find enclosed the REVISED manuscript:

“CANINE PROSTATE SPECIFIC ESTERASE (CPSE) AS AN USEFUL BIOMARKER IN PREVENTIVE SCREENING PROGRAM OF CANINE PROSTATE: CPSE THRESHOLD VALUE ASSESSMENT AND ITS CORRELATION WITH ULTRASONOGRAPHIC PROSTATIC ABNORMALITIES IN ASYMPTOMATIC DOGS.”

by Salvatore ALONGE, Monica MELANDRI, Raffaella LEOCI,

Giovanni Michele LACALANDRA, and Giulio AIUDI

The REVISED manuscript and “Point to Point reply to reviewers” (see below) have been approved by all co-authors.

Correspondence regarding the paper should be directed to the following address:

**Dr. Salvatore ALONGE**

Department of DETO, Section of Veterinary Clinics and Animal Productions  
University of Bari.

Str. Prov. Per Casamassima Km 3

70010, Valenzano, BA, Italy.

Phone +39 392,8058524

e-mail [drsalvatorealonge@gmail.com](mailto:drsalvatorealonge@gmail.com)

Thank you for your attention.

Yours sincerely,

*Salvatore Alonge*

1  
2  
3 Manuscript ID RDA-OA-Sep-2017-0367

4 entitled "CANINE PROSTATE SPECIFIC ESTERASE (CPSE) AS AN USEFUL  
5 BIOMARKER IN PREVENTIVE SCREENING PROGRAM OF CANINE  
6 PROSTATE: CPSE THRESHOLD VALUE ASSESSMENT AND ITS  
7 CORRELATION WITH ULTRASONOGRAPHIC PROSTATIC  
8 ABNORMALITIES IN ASYMPTOMATIC DOGS"  
9  
10  
11  
12  
13

14 The paper has been revised according to the Reviewer's suggestions.

15 We thank for the constructive criticism which contribute to improve the quality of the paper.  
16  
17  
18

19 Referee(s)' Comments to Author:

20 Referee: 1

21 Comments to the Author  
22  
23  
24

25  
26 The article is interesting and has clinical application of the marker CPSE  
27  
28

29 Introduction

30  
31 Line 45 : Specify the validity of ultrasonography in the diagnosis of prostate diseases also  
32 associated with the use of contrast agent such as indicated in the article CONTRAST-  
33 ENHANCED ULTRASOUND OF THE NORMAL CANINE PROSTATE GLAND  
34 Bigliardi E. Veterinary Radiology & Ultrasound 2011, Doppler ultrasound of the prostate in  
35 normal dogs and in dogs with chronic lymphocytic-lymphoplasmocytic prostatitis. Newell  
36 SM, Veterinary Radiology & Ultrasound 1998  
37  
38  
39

40 *Authors: Please, see line 46, this text was added.*  
41

42  
43 *In clinical veterinary practice, the most commonly used methods to diagnose canine*  
44 *prostatic gland diseases are digital rectal examination and abdominal ultrasound (Newell et*  
45 *al., 1998; Mukaratirwa and Chitura, 2007; Mantziaras et al., 2017). Recently some authors*  
46 *suggested that the monitoring of local blood flow by Doppler or Contrast-Enhanced*  
47 *UltraSonography is helpful in differentiating prostatic physio-pathological conditions*  
48 *(Bigliardi and Ferrari 2011; Russo et al., 2012; Troisi et al., 2015; Alonge et al., 2017).*  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 Material and Methods  
59  
60

1  
2  
3 Line 66: the common position for ultrasonography evaluation of prostate is dorsal  
4 recumbency that allows the evaluation of both lobes, constant relationships with surrounding  
5 structures and similar projections  
6

7  
8 *Authors: The patient was accurately examined in the lateral recumbency in order to*  
9 *minimize the necessary restraint.*  
10

11  
12  
13 Line 68: the 7,5 MHz probe in dog with BW >25 kg is not appropriate (5 Mhz)

14 *Authors: We agree, the line was corrected 5-7.5 MHz (lines 73)*  
15  
16

17  
18 Line 70: Specify the parameters used to evaluate the alterations of ecogenicity, symmetry,  
19 position etc.

20  
21 *Authors: Parameters (and literature) were specified (see lines 77-80).*  
22

23 *The normal intact canine prostate gland is mainly located in the pelvic region and only the*  
24 *cranial part of the gland is located in the abdominal cavity. The echogenicity, similar to that*  
25 *in the spleen, is fairly uniform with a smooth, stippled texture. Its shape is symmetrically*  
26 *bilobed in the transverse plane and oval in the longitudinal plane (Gobello and Corrada,*  
27 *2002; Davidson and Baker, 2009).*  
28  
29  
30  
31

32  
33 Result

34  
35 Line 88: Specifies how many dogs had alterations related to changes in ecogenicity, cysts,  
36 gland border alteration, and so on.

37  
38 *Authors: More detailed results were reported (see lines 95-100).*  
39

40 *As reported in table 1, 11 out of the 19 dogs examined, showed ultrasonographically altered*  
41 *prostate (group A, 2-5 years). Five dogs out from the eight that showed cysts, presented also*  
42 *one or more other US abnormalities [altered parenchyma echogenicity (n.=3), asymmetrical*  
43 *lobes (n.=1), gland border alteration (n.=3)]. Three dogs presented altered*  
44 *echotexture/echogenicity and/or irregular gland borders. Finally, in the remaining eight*  
45 *dogs (group B, 1-3 years) prostate was considered normal.*  
46  
47  
48  
49

50  
51 If the Authors have evaluated the levels of acid phosphatase in relation with CPSE can be  
52 useful.

53  
54 *Authors: We appreciate your suggestion but unfortunately these Acid Phosphatase levels have*  
55 *not been evaluated in this study thus we cannot describe any relation between them and the*  
56 *CPSE level.*  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Referee: 2

### Comments to the Author

#### General comments:

This is submission which lies perfectly in the scope of the journal. Scientifically elaborated clinical work. Authors analysed the CPSE blood concentration in the group of normal dogs and prostatomegalic dogs, both groups asymptomatic. It was proved that the concentration of CPSE in dogs with prostatomegaly is far higher. The cut off values of CPSE between normal/abnormal group is 50 ng/mL. Interesting observation. Interesting especially for practitioners, because it may be helpful in daily work-for example for screening examinations.

The drawback of this submission is that authors did not performed histological confirmation of BPH. It would be more professional to add such a confirmation. But we have to know that it would be nearly impossible in routine practice. No one owner would agree to perform prostate biopsy in asymptomatic dog.

*Authors: We agree and we have added the following sentences (lines 147-152).*

*In the present study the concentration of CPSE was significantly associated with the presence of prostatic abnormal findings that could be identified by the ultrasound exam.*

*Although, a histological confirmation of prostatic disease would have been desirable to definitively confirm the diagnosis, it is nearly impossible also in everyday routine practice when no one owner would agree to perform a more invasive procedure in an asymptomatic and apparently healthy dog, such as the prostate biopsy. On the other hand, the CPSE is a known marker for prostatic secretion, that can be easily assessed by a simple blood serum sample. It constitutes more than 90% of seminal proteins in dogs, but its exact role in the different prostatic disorders is not yet completely understood (Frenette et al., 1987; Gobello et al., 2002).*



1  
2  
3 And also another suggestions. Authors did not compare nor mentioned about recent  
4 publication of Pasikowska et al., who used CT and tried to establish some measuring system  
5 aiming similarly to authors of this submission.  
6  
7

8 *Authors: We agree and we have added these sentences (see lines 114-124).*

9  
10 *This study confirms that CPSE represents a useful tool to early detect prostatic disorders in*  
11 *dogs. Some authors have previously suggested that prostate size could be affected by age,*  
12 *breed, and body weight, but also by the emergence of pathologic processes, making the*  
13 *establishment of normal dimensions difficult because of the wide variety of canine sizes,*  
14 *breeds and conditions (O'Shea, 1962; Cartee and Rowels, 1983; Atalan et al., 1999; Smith,*  
15 *2008; Freitas et al., 2015). Several studies were performed in order to correctly establish the*  
16 *actual prostatic volume, through the two dimensional ultrasonographic prostatic measures.*  
17 *(Ruel et al., 1998; Atalan et al., 1999; Kamolpatana et al., 2000; Gobello and Corrada*  
18 *2002). Moreover, it was stated that the ultrasonographic exam is a highly dependent*  
19 *diagnostic imaging modality whose measurements accuracy might depend by the operator's*  
20 *ability and experience (Leroy et al., 2013). Thus, recently the Computed Tomography exam*  
21 *of the prostate was proposed (Dimitrov et al., 2010; Lee et al., 2011; Pasikowsha et al.,*  
22 *2015). The Computed Tomography examination would allow a more precise and repeatable*  
23 *measurements inter-observers, but it is less accessible, more expensive and time consuming,*  
24 *and requires general anesthesia (Pasikowsha et al., 2015). On the other hand, the*  
25 *ultrasonographic exam of the canine prostate is non-invasive and fast and so it remains the*  
26 *diagnostic imaging tool of choice for the evaluation of this organ (Levy et al., 2014;*  
27 *Mantziaras et al., 2017). Anyway, for all these reasons, since a clear threshold measure to*  
28 *identify the normal volume of the canine prostate dogs does not exist, in the present study*  
29 *dogs were grouped in accordance to presence/absence of other ultrasonographical*  
30 *abnormal findings (i.e. altered appearance, border, cysts).*  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 I have to say that also some biochemists (for example Mogielnicka-Brzozowska) published  
47 recently papers focused on analysis of CPSE by use proteomic methods and mentioned about  
48 would be also aimful, interesting for readers and may scientifically deepen Discussion. I  
49 found mentioned publications as very inspiring and I suggest to add them to references,  
50 cause authors cited a little older publications on CPSE.

51  
52 *Authors: We thank for the proper suggestion, we added this sentence (see lines 154-157).*

53  
54  
55 *Recently, it was suggested that the CPSE is secreted in the form of prostasomes (prostate*  
56 *granules) to semen during ejaculation. The activity of CPSE is regulated by the level of*  
57  
58  
59  
60

1  
2  
3 available zinc that is of great importance for maintaining the normal functions of the  
4 prostate and the spermatozoa. (Mogielnicka-Brzozowska et al., 2015).  
5  
6

7  
8 Specific comments:

9  
10 It is exception that I have no comments. Text is carefully prepared and I agree with all theses  
11 of authors. The language is correct. The tile, aim, M&M and results are adequately written. I  
12 attached the file with only one simple mistake in spelling

13  
14 *Authors: Thank you, we added your correction (see line 132).*  
15  
16

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review